

Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival and quality of life in stage III colon cancer and the effect of oxaliplatin: a pooled analysis of individual patient data from four randomised trials

Lancet Oncology, The

15, 1481-1492

DOI: [10.1016/s1470-2045\(14\)70486-3](https://doi.org/10.1016/s1470-2045(14)70486-3)

Citation Report

#	ARTICLE	IF	CITATIONS
1	How can we improve adjuvant chemotherapy for colon cancer?. <i>Lancet Oncology</i> , The, 2014, 15, 1413-1415.	5.1	0
2	Efficacy and Safety of Capecitabine and Oxaliplatin (CapOX) as an Adjuvant Therapy in Japanese for Stage II/III Colon Cancer in a Group at High Risk of Recurrence in Retrospective Study. <i>Oncology Research</i> , 2015, 22, 325-331.	0.6	5
3	New Neoadjuvant Treatment Strategies for Non-Metastatic Rectal Cancer (M0). <i>Current Colorectal Cancer Reports</i> , 2015, 11, 289-297.	1.0	0
5	Dynamic monitoring of plasma amino acids and carnitine during chemotherapy of patients with alimentary canal malignancies and its clinical value. <i>OncoTargets and Therapy</i> , 2015, 8, 1989.	1.0	7
7	KRAS as a predictor of poor prognosis and benefit from postoperative FOLFOX chemotherapy in patients with stage II and III colorectal cancer. <i>Molecular Oncology</i> , 2015, 9, 1341-1347.	2.1	37
8	Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials. <i>Annals of Oncology</i> , 2015, 26, 715-724.	0.6	104
9	Adjuvant Systemic Therapy in Stage II and III Colon Cancer. , 2016, , .		0
10	Retrospective Analysis of the Effect of CAPOX and mFOLFOX6 Dose Intensity on Survival in Colorectal Patients in the Adjuvant Setting. <i>Current Oncology</i> , 2016, 23, 171-177.	0.9	8
11	Increased Calcineurin A Expression Is Associated with a Lower Relapse-Free Survival Rate after Colorectal Cancer Surgery. <i>Pathobiology</i> , 2016, 83, 308-315.	1.9	1
12	Prodrug Strategy in Drug Development. <i>Acta Marisiensis - Seria Medica</i> , 2016, 62, 356-362.	0.3	30
13	Phase 1 study on S-1 and oxaliplatin therapy as an adjuvant after hepatectomy for colorectal liver metastases. <i>Investigational New Drugs</i> , 2016, 34, 468-473.	1.2	1
15	Is There a Best Radiosensitizing Agent in the Treatment of Locally Advanced Rectal Cancer?. <i>Current Colorectal Cancer Reports</i> , 2016, 12, 189-200.	1.0	2
16	Adjuvant chemotherapy and relative survival of patients with stage II colon cancer â€” A EURECCA international comparison between the Netherlands, Denmark, Sweden, England, Ireland, Belgium, and Lithuania. <i>European Journal of Cancer</i> , 2016, 63, 110-117.	1.3	24
17	Optimizing adjuvant therapy and survivorship care of stage III colon cancer. <i>Future Oncology</i> , 2016, 12, 2021-2035.	1.1	12
18	Advances in adjuvant therapy of colon cancer. <i>Seminars in Colon and Rectal Surgery</i> , 2016, 27, 204-212.	0.2	0
19	Personalizing fluoropyrimidine administration in colorectal cancer patients. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 289-299.	0.4	0
20	5-Fluorouracil shell-enriched solid lipid nanoparticles (SLN) for effective skin carcinoma treatment. <i>Drug Delivery</i> , 2016, 23, 3452-3460.	2.5	77
21	Diabetes and Body Mass Index Are Associated with Neuropathy and Prognosis in Colon Cancer Patients Treated with Capecitabine and Oxaliplatin Adjuvant Chemotherapy. <i>Oncology</i> , 2016, 90, 36-42.	0.9	60

#	ARTICLE	IF	CITATIONS
22	Systemic capillary leak syndrome in a patient receiving adjuvant oxaliplatin for locally advanced colon cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 725-728.	0.5	9
23	Changes in Noninvasive Liver Fibrosis Indices and Spleen Size During Chemotherapy. <i>Medicine (United States)</i> 2017, 96, 1-10.	0.4	23
24	Population-Based Cost-Minimization Analysis of CAPOX Versus Modified FOLFOX6 in the Adjuvant Treatment of Stage III Colon Cancer. <i>Clinical Colorectal Cancer</i> , 2016, 15, 158-163.	1.0	4
25	Rectal cancer: French Intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). <i>Digestive and Liver Disease</i> , 2017, 49, 359-367.	0.4	65
26	Influence of age and comorbidity on prognosis and application of adjuvant chemotherapy in elderly Japanese patients with colorectal cancer: A retrospective multicentre study. <i>European Journal of Cancer</i> , 2017, 81, 90-101.	1.3	52
27	Challenges behind proving efficacy of adjuvant chemotherapy after preoperative chemoradiation for rectal cancer. <i>Lancet Oncology</i> , The, 2017, 18, e354-e363.	5.1	89
28	Randomized Clinical Trials in Colon and Rectal Cancer. <i>Surgical Oncology Clinics of North America</i> , 2017, 26, 689-704.	0.6	26
29	The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Treatment of Colon Cancer. <i>Diseases of the Colon and Rectum</i> , 2017, 60, 999-1017.	0.7	242
30	Oral versus intravenous fluoropyrimidines for colorectal cancer. <i>The Cochrane Library</i> , 2017, 2017, CD008398.	1.5	23
31	Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. <i>European Journal of Cancer</i> , 2017, 82, 16-24.	1.3	40
32	The effect of geriatric intervention in frail elderly patients receiving chemotherapy for colorectal cancer: a randomized trial (GERICO). <i>BMC Cancer</i> , 2017, 17, 448.	1.1	32
33	Preoperative Serum Carcinoembryonic Antigen Level as a Prognostic Factor for Recurrence and Survival After Curative Resection Followed by Adjuvant Chemotherapy in Stage III Colon Cancer. <i>Annals of Surgical Oncology</i> , 2017, 24, 227-235.	0.7	39
35	Neoadjuvant Chemotherapy With Capecitabine Plus Cisplatin in Patients With Locally Advanced Nasopharyngeal Cancer: Case Series Study. <i>Journal of Global Oncology</i> , 2017, 3, 455-458.	0.5	3
36	Antitumor activity of a molecularly imprinted nanopreparation of 5-fluorouracil against Ehrlich's carcinoma solid tumors grown in mice: Comparison to free 5-fluorouracil. <i>Chemico-Biological Interactions</i> , 2018, 295, 52-63.	1.7	15
37	Are Capecitabine and 5FU Equivalent When Combined with Radiotherapy?. , 2018, , 259-262.		0
38	Survival Impact of CAPOX Versus FOLFOX in the Adjuvant Treatment of Stage III Colon Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, 156-163.	1.0	24
39	Trends in presentation, treatment and survival of 1777 patients with colorectal cancer over a decade: a Biobank study. <i>Acta Oncologica</i> , 2018, 57, 735-742.	0.8	6
40	A new look at the International Duration Evaluation of Adjuvant therapy (IDEA) classification—Defining novel predictive and prognostic markers in stage III colon cancer. <i>European Journal of Cancer</i> , 2018, 96, 105-110.	1.3	5

#	ARTICLE	IF	CITATIONS
41	Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. <i>JAMA Oncology</i> , 2018, 4, e180071.	3.4	404
42	Treatment and Survival of Patients with Colon Cancer Aged 80 Years and Older: A EURECCA International Comparison. <i>Oncologist</i> , 2018, 23, 982-990.	1.9	17
43	Elevated serum levels of proinflammatory cytokines potentially correlate with depression and anxiety in colorectal cancer patients in different stages of the antitumor therapy. <i>Cytokine</i> , 2018, 104, 72-77.	1.4	33
44	Colon Cancer: The Road Traveled. <i>Surgical Oncology Clinics of North America</i> , 2018, 27, xv-xviii.	0.6	7
45	Total mesorectal excision with or without preoperative chemoradiotherapy for resectable mid/low rectal cancer: a long-term analysis of a prospective, single-center, randomized trial. <i>Cancer Communications</i> , 2018, 38, 1-10.	3.7	9
46	Rationale for the administration of systemic 5-FU in combination with heated intraperitoneal oxaliplatin. <i>Surgical Oncology</i> , 2018, 27, 275-279.	0.8	6
48	Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial. <i>BMC Cancer</i> , 2018, 18, 449.	1.1	35
49	Use of adjuvant chemotherapy in patients with stage III colon cancer in Puerto Rico: A population-based study. <i>PLoS ONE</i> , 2018, 13, e0194415.	1.1	11
50	Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single-center experience. <i>Cancer Communications</i> , 2019, 39, 1-12.	3.7	6
51	Polymorphisms of <i>MTHFR</i> and <i>TYMS</i> predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer. <i>Cancer Communications</i> , 2019, 39, 1-12.	3.7	7
52	Does adjuvant chemotherapy improve the prognosis of patients after resection of pulmonary metastasis from colorectal cancer? A systematic review and meta-analysis. <i>International Journal of Colorectal Disease</i> , 2019, 34, 1661-1671.	1.0	14
53	Mismatch Repair System Deficiency Is Associated With Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 824-833.	0.4	25
54	Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project. <i>Annals of Oncology</i> , 2019, 30, 1304-1310.	0.6	28
55	Does adjuvant therapy reduce postmetastatic survival?. <i>Annals of Oncology</i> , 2019, 30, 1184-1188.	0.6	12
56	<p><p>A review of small molecules and drug delivery applications using gold and iron nanoparticles</p>. <i>International Journal of Nanomedicine</i> , 2019, Volume 14, 1633-1657.	3.3	155
57	Treatment of Patients With Early-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline. <i>Journal of Global Oncology</i> , 2019, 5, 1-19.	0.5	68
58	Synchronous Gastrointestinal Tumor and Abdominal Aortic Aneurysm or Dissection Treated with Endovascular Aneurysm Repair Followed by Tumor Resection. <i>Gastroenterology Research and Practice</i> , 2019, 2019, 1-7.	0.7	3
59	Refining the Use of Adjuvant Oxaliplatin in Clinical Stage II or III Rectal Adenocarcinoma. <i>Oncologist</i> , 2019, 24, e671-e676.	1.9	5

#	ARTICLE	IF	CITATIONS
60	Differential Survival Benefits of 5-Fluorouracil-Based Adjuvant Chemotherapy for Patients With Microsatellite-Stable Stage III Colorectal Cancer According to the Tumor Budding Status: A Retrospective Analysis. <i>Diseases of the Colon and Rectum</i> , 2019, 62, 1316-1325.	0.7	10
61	Recent Advances in the Treatment of Colorectal Cancer. , 2019, , .		2
62	Adjuvant Chemotherapy. , 2019, , 81-100.		0
63	Efficacy of adjuvant chemotherapy after resection of pulmonary metastasis from colorectal cancer: a propensity score-matched analysis. <i>European Journal of Cancer</i> , 2019, 106, 69-77.	1.3	23
64	Construction and validation of a simple scoring system for stage III colorectal cancer recurrence (SiS-SCORE). A case control study. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 238-244.	0.6	0
65	Effect of Neoadjuvant Systemic Chemotherapy With or Without Chemoradiation on Bowel Function in Rectal Cancer Patients Treated With Total Mesorectal Excision. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 800-807.	0.9	21
66	TLR 7/8 agonist reverses oxaliplatin resistance in colorectal cancer via directing the myeloid-derived suppressor cells to tumoricidal M1-macrophages. <i>Cancer Letters</i> , 2020, 469, 173-185.	3.2	95
67	Efficacy and tolerability of adjuvant therapy in a 70-year-old patients with T3N0M0 colorectal cancer: An observational study. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 619-631.	0.5	3
68	In favor of total neoadjuvant therapy (TNT) for locally advanced rectal carcinoma. <i>Clinical and Translational Oncology</i> , 2020, 22, 793-794.	1.2	0
69	Novel exosomal miR-46146 transfer oxaliplatin chemoresistance in colorectal cancer. <i>Clinical and Translational Oncology</i> , 2020, 22, 1105-1116.	1.2	26
70	The local immune phenotype influences prognosis in patients with nodal-positive rectal cancer after neoadjuvant chemoradiation. <i>International Journal of Colorectal Disease</i> , 2020, 35, 365-370.	1.0	5
71	Lessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V.1.1. <i>ESMO Open</i> , 2020, 5, e000681.	2.0	5
72	Model-based evaluation of the cost effectiveness of 3 versus 6 months adjuvant chemotherapy in high-risk stage II colon cancer patients. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482095411.	1.4	3
73	Feasibility Study of a Modified XELOX Adjuvant Chemotherapy for High-Recurrence Risk Patients With Operated Stage III Colon Cancer. <i>Frontiers in Pharmacology</i> , 2020, 11, 583091.	1.6	4
74	Oxaliplatin-induced increase in splenic volume: experiences from multicenter study in Japan. <i>International Journal of Clinical Oncology</i> , 2020, 25, 2075-2082.	1.0	2
75	Comprehensive literature review of randomized clinical trials examining novel treatment advances in patients with colon cancer. <i>Journal of Gastrointestinal Oncology</i> , 2020, 11, 790-802.	0.6	8
76	Impact of Anatomic Extent of Nodal Metastasis on Adjuvant Chemotherapy Outcomes in Stage III Colon Cancer. <i>Diseases of the Colon and Rectum</i> , 2020, 63, 1455-1465.	0.7	0
77	Kanglaite injection plus fluorouracil-based chemotherapy on the reduction of adverse effects and improvement of clinical effectiveness in patients with advanced malignant tumors of the digestive tract. <i>Medicine (United States)</i> , 2020, 99, e19480.	0.4	10

#	ARTICLE	IF	CITATIONS
78	How should colorectal surgeons practice during the COVID-19 epidemic? A retrospective single-centre analysis based on real-world data from China. ANZ Journal of Surgery, 2020, 90, 1310-1315.	0.3	9
79	Development and clinical application of bispecific antibody in the treatment of colorectal cancer. Expert Review of Clinical Immunology, 2020, 16, 689-709.	1.3	5
80	Mismatch Repair-Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy. Clinical Cancer Research, 2020, 26, 3271-3279.	3.2	118
81	Pharmacological cancer treatment and venous thromboembolism risk. European Heart Journal Supplements, 2020, 22, C2-C14.	0.0	11
82	Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer – Results of the international randomized RAPIDO-trial. Radiotherapy and Oncology, 2020, 147, 75-83.	0.3	132
83	Tumour size and overall survival among surgically treated patients with non-metastatic colon cancer in the U.S. Military Health System. Colorectal Disease, 2021, 23, 192-199.	0.7	3
84	The clinical features, management, and survival of elderly patients with colorectal cancer. Journal of Gastrointestinal Oncology, 2021, 12, 89-99.	0.6	5
85	Phase II study of an oxaliplatin-based regimen for relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy (INSPIRE study). Cancer Chemotherapy and Pharmacology, 2021, 87, 665-672.	1.1	1
86	Long-term outcomes of single-incision versus multiport laparoscopic colectomy for colon cancer: results of a propensity score-based analysis. Surgical Endoscopy and Other Interventional Techniques, 2022, 36, 1027-1036.	1.3	5
87	Comparative analysis of the Memorial Sloan Kettering Bowel Function Instrument and the Low Anterior Resection Syndrome Questionnaire for assessment of bowel dysfunction in rectal cancer patients after low anterior resection. Colorectal Disease, 2021, 23, 451-460.	0.7	16
88	A Triptolide Loaded HER2-Targeted Nano-Drug Delivery System Significantly Suppressed the Proliferation of HER2-Positive and BRAF Mutant Colon Cancer. International Journal of Nanomedicine, 2021, Volume 16, 2323-2335.	3.3	8
89	Appearance of Focal Nodular Hyperplasia after Chemotherapy in Two Patients during Follow-Up of Colon Carcinoma. Case Reports in Surgery, 2021, 2021, 1-4.	0.2	1
90	Early liver metastases after ‘failure’ of adjuvant chemotherapy for stage III colorectal cancer: is there a role for additional adjuvant therapy?. Hpb, 2021, 23, 601-608.	0.1	3
91	Tumor budding as a predictive marker for 5-fluorouracil response in adjuvant-treated stage III colorectal cancer. International Journal of Clinical Oncology, 2021, 26, 1285-1292.	1.0	2
92	The effect of geriatric intervention in frail older patients receiving chemotherapy for colorectal cancer: a randomised trial (GERICO). British Journal of Cancer, 2021, 124, 1949-1958.	2.9	82
93	ctDNA to Guide Adjuvant Therapy in Localized Colorectal Cancer (CRC). Cancers, 2021, 13, 2869.	1.7	19
94	Retrospective cohort analysis of prescription patterns of cancer medications during periods of drug stockouts in Botswana. BMJ Open, 2021, 11, e049574.	0.8	1
95	MRI radiomics features of mesorectal fat can predict response to neoadjuvant chemoradiation therapy and tumor recurrence in patients with locally advanced rectal cancer. European Radiology, 2022, 32, 971-980.	2.3	34

#	ARTICLE	IF	CITATIONS
96	Accurate population-based model for individual prediction of colon cancer recurrence. <i>Acta Oncologica</i> , 2021, 60, 1241-1249.	0.8	6
97	Cisplatin combined with capecitabine-induced chemotherapy for local nasopharyngeal carcinoma can improve the quality of life and reduce toxic and side effects. <i>World Journal of Surgical Oncology</i> , 2021, 19, 280.	0.8	2
98	Chemopreventive Effect of 5-Fluorouracil Polymeric Hybrid PLGA-Lecithin Nanoparticles against Colon Dysplasia Model in Mice and Impact on p53 Apoptosis. <i>Biomolecules</i> , 2021, 11, 109.	1.8	4
99	Building personalized treatment plans for early-stage colorectal cancer patients. <i>Oncotarget</i> , 2017, 8, 13805-13817.	0.8	13
100	Non-operative management of rectal cancer: understanding tumor biology. <i>Minerva Chirurgica</i> , 2018, 73, 601-618.	0.8	3
101	Loss of LKB1 Protein Expression Correlates with Increased Risk of Recurrence and Death in Patients with Resected, Stage II or III Colon Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 1518-1526.	1.3	10
102	The Influence of Adjuvant Chemotherapy Dose Intensity on Five-Year Outcomes in Resected Colon Cancer: A Single Centre Retrospective Analysis. <i>Current Oncology</i> , 2021, 28, 4031-4041.	0.9	5
103	D-MT prompts the anti-tumor effect of oxaliplatin by inhibiting IDO expression in a mouse model of colon cancer. <i>International Immunopharmacology</i> , 2021, 101, 108203.	1.7	5
104	Cancer du clon non mtastatique : dscalade thrapeutique. <i>Colon and Rectum</i> , 2018, 12, 161-169.	0.0	0
105	Inhibition of the PLK1Coupled Cell Cycle Machinery Overcomes Resistance to Oxaliplatin in Colorectal Cancer. <i>Advanced Science</i> , 2021, 8, e2100759.	5.6	29
106	Optionen der neoadjuvanten Therapie beim Rektumkarzinom. , 2020, , 79-88.		0
107	Mechanistic and Therapeutic Advances in Colon Cancer: A Systematic Review. , 0, , 001-012.		0
108	Adjuvant chemotherapy for colon cancer: a consensus statement of the Hellenic and Cypriot Colorectal Cancer Study Group by the HeSMO. <i>Annals of Gastroenterology</i> , 2016, 29, 18-23.	0.4	3
109	miR-34a increases the sensitivity of colorectal cancer cells to 5-fluorouracil and. <i>American Journal of Cancer Research</i> , 2018, 8, 280-290.	1.4	11
110	The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Colon Cancer. <i>Diseases of the Colon and Rectum</i> , 2022, 65, 148-177.	0.7	118
111	Development and Assessment of a Clinical Calculator for Estimating the Likelihood of Recurrence and Survival Among Patients With Locally Advanced Rectal Cancer Treated With Chemotherapy, Radiotherapy, and Surgery. <i>JAMA Network Open</i> , 2021, 4, e2133457.	2.8	16
112	Targeted deep sequencing reveals APC mutations as predictors of overall survival in Chinese colorectal patients receiving adjuvant chemotherapy. <i>Scandinavian Journal of Gastroenterology</i> , 2022, , 1-8.	0.6	0
113	JCOG0603: Are We Really Sure This Was a Negative Trial?. <i>Journal of Clinical Oncology</i> , 2022, 40, 803-805.	0.8	1

#	ARTICLE	IF	CITATIONS
114	Coronary Artery Disease and Cancer: Treatment and Prognosis Regarding Gender Differences. <i>Cancers</i> , 2022, 14, 434.	1.7	6
115	Whether Patients With Stage â...j/â...ç Colorectal Cancer Benefit From Adjuvant Chemotherapy: A Modeling Analysis of Literature Aggregate Data. <i>Frontiers in Pharmacology</i> , 2022, 13, 826785.	1.6	6
116	Kolonkarzinom. , 2022, , 313-334.		0
117	Perioperative second-line chemotherapy is beneficial for resectable liver metastases that occur during or early after adjuvant chemotherapy for colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2022, 37, 805-814.	1.0	0
118	Modeling the Cost-Effectiveness of Adjuvant Chemotherapy for Stage III Colon Cancer in South African Public Hospitals. <i>JCO Global Oncology</i> , 2021, 7, 1730-1741.	0.8	3
119	Proton pump inhibitors affect capecitabine efficacy in patients with stage IIâ€“III colorectal cancer: a multicenter retrospective study. <i>Scientific Reports</i> , 2022, 12, 6561.	1.6	10
120	Total Neoadjuvant Strategies for Locally Advanced Rectal Cancer. <i>Advances in Oncology</i> , 2022, 2, 227-236.	0.1	1
121	Adjuvant chemotherapy is associated with improved overall survival in select patients with Stage II colon cancer: A National Cancer Database analysis. <i>Journal of Surgical Oncology</i> , 2022, 126, 748-756.	0.8	4
122	HOTAIR/miR-1277-5p/ZEB1 axis mediates hypoxia-induced oxaliplatin resistance via regulating epithelial-mesenchymal transition in colorectal cancer. <i>Cell Death Discovery</i> , 2022, 8, .	2.0	14
123	Constructing turn-on bioluminescent probes for real-time imaging of reactive oxygen species during cisplatin chemotherapy. <i>Biosensors and Bioelectronics</i> , 2022, 216, 114632.	5.3	3
124	Real impact of oxaliplatin in adjuvant chemotherapy for patients with stage III colon cancer based on the Multi-Institutional Registry of Large Bowel Cancer in Japan. <i>Global Health & Medicine</i> , 2022, , .	0.6	0
126	Retrospective Analysis of the Safety of FOLFOX Compared to CAPOX for Adjuvant Treatment of Stage III Colorectal Cancer in Newfoundland Patients. <i>Gastrointestinal Disorders</i> , 2022, 4, 214-222.	0.4	0
127	Lymphovascular invasion represents a superior prognostic and predictive pathological factor of the duration of adjuvant chemotherapy for stage III colon cancer patients. <i>BMC Cancer</i> , 2023, 23, .	1.1	1
128	FOxTROT: Are We Ready to Dance?. <i>Journal of Clinical Oncology</i> , 2023, 41, 1514-1517.	0.8	3
129	Does the Gain of Total Neoadjuvant Therapy Outweigh the Harm in Rectal Cancer? Importance of the ATRESS (neoAdjuvant Therapy-Related Shortening of Survival) Phenomenon: A Systematic Review. <i>Cancers</i> , 2023, 15, 1016.	1.7	3
130	Long-term platinum-based drug accumulation in cancer-associated fibroblasts promotes colorectal cancer progression and resistance to therapy. <i>Nature Communications</i> , 2023, 14, .	5.8	15
131	LncRNA-NEF suppressed oxaliplatin resistance and epithelial-mesenchymal transition in colorectal cancer through epigenetically inactivating MEK/ERK signaling. <i>Cancer Gene Therapy</i> , 2023, 30, 855-865.	2.2	6